Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
- Stocks near record highs on recovery hopes, Curevac sinks
- PayPal (PYPL) Tops Q1 EPS by 21c, Offers Q2 and FY Guidance
- Tesla (TSLA) demand is through the roof, already sold out this quarter - Electrek
- Dollar falls as risk appetite improves, sterling steady before BoE
- Uber (UBER) Tops Q1 EPS by 47c, Revenue Misses
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 6, 2021, following the release of its first quarter 2021 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Source: Puma Biotechnology, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: EPAM Systems (EPAM) Tops Q1 EPS by 13c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus, 2Q EPS/Revs. View Above Consensus
- Sally Beauty Holdings Reports Strong Sales, Gross Margin and Profit Growth For Fiscal 2021 Second Quarter Despite Pandemic Disruptions
- Tapestry, Inc. Reports Fiscal 2021 Third Quarter Results
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Related EntitiesEarnings, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!